Biotech Values

[DewDiligence]

I don't remember having seen SVR or ETR data for rib + DAA (wo IFN) from any trial. But perhaps I missed it?

The data VRTX is speaking of are deductive and stem from the omission of ribavirin rather than the omission of IFN. In VRTX’s PROVE-2 study (but not the PROVE-1 study), one trial arm had 80 patients who received Telaprevir + IFN without ribavirin and these patients did badly—see #msg-11248731 and #msg-28746843.